Neuromyelitis optica spectrum disorders

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 5, 2010, Pages 105-121

  Wingerchuk, Dean M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINUCLEAR ANTIBODY; AQUAPORIN 4; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; RITUXIMAB;

ARTICLE; BRAIN DAMAGE; BRAIN STEM; CERVICAL SPINAL CORD; CLINICAL FEATURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; LEUKOCYTE COUNT; MULTIPLE SCLEROSIS; MUSCLE SPASM; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PARAPLEGIA; PATHOGENESIS; PLASMAPHERESIS; PLEOCYTOSIS; POLYMORPHONUCLEAR CELL; PREVALENCE; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; SPINAL CORD; THORAX PAIN; TREATMENT DURATION; VERTIGO; VISUAL ACUITY; VISUAL DISORDER;

EID: 78650722767     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000389937.69413.15     Document Type: Article

References (51)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(4):1107-1114.
2. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56(4):507-514.
3. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodriǵuez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009;256(1):35-44.
4. Rivera JF, Kurtzke JF, Booth VJ, et al. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 2008;255(5):710-715.
5. Bedi G, Usmani N, Delgado S, Sheremata W. Prevalence and ethnic origin of patients with neuromyelitis optica in South Florida. Mult Scler 2009;15:S34.
6. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009;256(11):1891-1898.
7. Wingerchuk DM. Neuromyelitis optica: Effect of gender. J Neurol Sci 2009; 286(1-2):18-23.
8. Green AJ, Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 2009;80(9):1002-1005.
9. Misu T, Fujihara K, Nakashima I, et al. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65(9):1479-1482.
10. Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008;70(5):344-352.
11. Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005;11(5):617-621.
12. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72(8):712-717.
13. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485-1489.
14. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: A consensus approach. Mult Scler 2008;14(9):1157-1174.
15. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65(1):78-83.
16. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68(8):603-605.
17. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59(3): 566-569.
18. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70(23):2197-2200.
19. Takahashi T, Fujihara K, Nakashima I, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007;130(pt 5):1235-1243.
20. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6(9):805-815.
21. Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: A multicenter study of 125 patients. Neurology 2010;74(9):736-742.
22. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63(3):390-396.
23. Ito S, Mori M, Makino T, et al. "Cloud-like enhancement'' is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009;66(3):425-428.
24. Nakamura M, Misu T, Fujihara K, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 2009;15:695-700.
25. McKeon A, Lennon VA, Jacob A, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39(1):87-90.
26. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364(9541): 2106-2112.
27. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: Current status of the assays. Int MS J 2008;15(3):99-105.
28. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: Comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol 2009;66(9):1134-1138.
29. Klawiter EC, Alvarez E 3rd, Xu J, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 2009;72(12):1101-1103.
30. Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65(5):629-632.
31. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131(pt 11):3072-3080.
32. Hinson SR, McKeon A, Fryer JP, et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch Neurol 2009;66(9):1164-1167.
33. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-477.
34. Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci 2003;4(12):991-1001.
35. Nicchia GP, Mastrototaro M, Rossi A, et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009;57(13):1363-1373.
36. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125(pt 7):1450-1461.
37. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130(pt 5):1194-1205.
38. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007;69(24):2221-2231.
39. Vincent T, Saikali P, Cayrol R, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181(8):5730-5737.
40. Hinson SR, Roemer SF, Lucchinetti CF, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008;205(11):2473-2481.
41. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66(5):630-643.
42. Bennett L, Lam C, Reddy Kalluri S, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66(5):617-629.
43. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009;386(4):623-627.
44. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133(pt 2):349-361.
45. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46(6):878-886.
46. Bonnan N, Valentino R, Olindo S, et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009;15(4): 487-492.
47. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008;10(1):55-66.
48. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13(2):256-259.
49. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: Retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128-1133.
50. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64(7):1270-1272.
51. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443-1448.